Access Biotechnology

About The Fund

Access Biotechnology is an investment arm of Access Industries, a global investment company founded by businessman and philanthropist Len Blavatnik. Positioning itself at the forefront of the biotech arena, Access Biotechnology specializes in funding transformative therapies for conditions with significant unmet needs, aspiring to have a profound impact on human health. Established in 2019 and directed by Liam Ratcliffe, a former head of worldwide clinical R&D at Pfizer, the fund boasts a portfolio comprising over 30 private and public biopharma investments and has achieved more than 5 successful exits. Their investment focus covers the full spectrum of biopharma companies – from discovery-stage technology platforms to late-stage clinical programs across various therapeutic areas, modalities, and development stages. Access Biotechnology is notable for its broad scope, long-term orientation, flexibility in adapting to the needs and fluctuations of the environment, technical rigor, and collaborative style. The fund partners with founders, management, and fellow investors to cultivate and advance companies that are in the business of developing crucial new medicines.Access Biotechnology carries a strong emphasis on fundamental value creation, investing in people, data, and innovation rather than momentum or hype. With minimum investment limits starting at $100,000 and maxing out at $5,000,000, the fund's sweet spot for investment typically resides around $1,500,000. They specialize in facilitating Seed, Series A, and Series B financing rounds. Success stories include participations in notable biotech ventures such as Disc Medicine, Climb Bio, Principia, and many more – some of which have been acquired by prime industry leaders like Sanofi, Merck, Novartis, and Takeda. These investments span a multitude of therapeutic areas and reflect an unwavering commitment to advancing medical science and patient care.